Effects on the eye: Sudden loss of vision could be a sign of non-arteritic ischemic optic neuropathy (NAION) and may be permanent .

Special Cases

Hearing impairment: Cases of sudden decrease or loss of hearing have been reported with CIALIS. Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. Prolonged erection: Advise patients to seek emergency treatment if an erection lasts >4 hours. The most common adverse reaction is headache.

  • Yellow Cialis pills contain the active ingredient tadalafil, used to treat erectile dysfunction.
  • The color yellow helps distinguish Cialis from other medications.
  • Cialis is available in various dosages, such as 5mg, 10mg, and 20mg, often in yellow pills.
  • Yellow Cialis pills are manufactured by Eli Lilly and others for erectile health.
  • The yellow color is a trademark for Cialis to ensure brand recognition.
  • Cialis pills, including yellow ones, can last up to 36 hours in the body.
  • The yellow Cialis pill is taken orally, usually 30 minutes before sexual activity.
  • Cialis is FDA-approved for treating both ED and benign prostatic hyperplasia (BPH).
  • Yellow Cialis pills may be prescribed for daily use or as needed.
  • Yellow Cialis pills are available via prescription or certain online pharmacies.
  • The yellow Cialis pill is known for its high bioavailability and quick onset.
  • Side effects of yellow Cialis include headaches, flushing, and upset stomach.

To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE1.1 Pulmonary Arterial Hypertension2 DOSAGE AND ADMINISTRATION2.1 Pulmonary Arterial Hypertension2.2 Dose Adjustment in Renal Impairment2.3 Dose Adjustment in Hepatic Impairment2.4 Dose Adjustment for Use with Ritonavir3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS4.1 Concomitant Organic Nitrates4.2 Concomitant Guanylate Cyclase (GC) Stimulators4.3 Hypersensitivity Reactions5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Visual Loss5.4 Hearing Impairment5.5 Combination with Other PDE5 Inhibitors5.6 Prolonged Erection6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 Nitrates7.2 Alpha-Blockers7.3 Antihypertensives7.4 Alcohol7.5 CYP3A Inhibitors/Inducers8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.3 Females and Males of Reproductive Potential8.4 Pediatric Use8.5 Geriatric Use8.6 Renal Impairment8.7 Hepatic Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology14 CLINICAL STUDIES14.1 Tadalafil tablets for Pulmonary Arterial Hypertension14.2 Long-Term Treatment of Pulmonary Arterial Hypertension16 HOW SUPPLIED/STORAGE AND HANDLING16.1 How Supplied16.2 Storage17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed. 1 INDICATIONS AND USAGE 1.1 Pulmonary Arterial HypertensionTadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

  • The yellow Cialis pill typically has embossed markings for identification.
  • Do not take yellow Cialis pills with nitrates due to dangerous interactions.
  • Yellow Cialis can be purchased as a generic or branded medication.
  • The medication is generally well tolerated when used as directed.
  • Yellow Cialis pills should be stored in a cool, dry place away from children.
  • Used correctly, yellow Cialis improves erectile function significantly.
  • The yellow pill's design prevents counterfeiting and ensures authenticity.
  • Cialis, including yellow tablets, should not be taken more than once per day.
  • Alcohol consumption can reduce the effectiveness of yellow Cialis pills.
  • Health care providers tailor Cialis dosage depending on age and health status.
  • The yellow Cialis pill's duration of action makes it popular among users.
  • Yellow Cialis pills are sometimes used recreationally, which is risky.

Tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. 2 DOSAGE AND ADMINISTRATION 2.1 Pulmonary Arterial HypertensionThe recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended.2.2 Dose Adjustment in Renal ImpairmentMild (creatinine clearance 51 to 80 buy cialis 5mg mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] .2.3 Dose Adjustment in Hepatic ImpairmentMild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day.Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied. Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] .2.4 Dose Adjustment for Use with RitonavirCo-administration of Tadalafil Tablets in Patients on RitonavirIn patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] .Co-administration of Ritonavir in Patients on Tadalafil TabletsAvoid use of tadalafil tablets during the initiation of ritonavir. Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] . The recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended. Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] .

Product Dosage Quantity + Bonus Price
Cialis Original20mg120 + 8 Pills497.29€ 473.61€
Cialis Generic20mg20 Pills54.72€ 52.11€
Cialis Generic10mg360 + 10 Pills388.49€ 369.99€
Cialis Generic20mg60 + 6 Pills117.76€ 112.15€
Cialis Original20mg22 + 2 Pills129.20€ 123.05€
Cialis Super Active20mg180 + 20 Pills521.59€ 496.75€
Cialis Generic2.5mg10 Pills28.51€ 27.15€
Cialis Soft Tabs20mg120 + 6 Pills248.64€ 236.80€
Cialis Professional40mg120 + 4 Pills436.68€ 415.89€
Cialis Professional20mg60 + 2 Pills183.83€ 175.08€

Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied. Avoid use of tadalafil tablets [see cialis 20mg tadalafil lilly Use in Specific Populations ( 8.7)] .

5.4 Hearing Impairment

Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] . Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied.

Your expert team

Avoid use of tadalafil tablets [see cialis 20mg tadalafil lilly Use in Specific Populations ( 8.7)] . Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir. 4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Do not use nitrates within 48 hours of the lst dose of tadalafil. Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily.

4. Generic tadalafil is no different from brand-name Cialis

Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.

What does Cialis look like?

Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir.

5.11 Combination With Other PDE5 Inhibitors or Erectile Dysfunction Therapies

4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Do not use nitrates within 48 hours of the lst dose of tadalafil. Tadalafil potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] .4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets).

Risks and warnings for Tadalafil (Cialis)

Tadalafil potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] .4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions ( 6.2)] . Tadalafil is contraindicated in patients who are cialis tadalafil 10 mg using any form of organic nitrate, either regularly or intermittently.

Medicine interactions

This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] . Coadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators. Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions ( 6.2)] . Tadalafil is contraindicated in patients who are cialis tadalafil 10 mg using any form of organic nitrate, either regularly or intermittently.

Ingredient Amount per Dose Purpose Notes
Tadalafil 20 mg Active ingredient, vasodilator Main component for ED
Microcrystalline Cellulose - Filler Binds ingredients
Magnesium Stearate - Excipient Improves pill stability
Titanium Dioxide - Coloring agent Provides yellow color

This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] . Coadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators. Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.

UK DOCTORS AND CLINICIANS

2 DOSAGE AND ADMINISTRATION 2.1 Pulmonary Arterial HypertensionThe recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended.2.2 Dose Adjustment in Renal ImpairmentMild (creatinine clearance 51 to 80 buy cialis 5mg mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] .2.3 Dose Adjustment in Hepatic ImpairmentMild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day.Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied. Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] .2.4 Dose Adjustment for Use with RitonavirCo-administration of Tadalafil Tablets in Patients on RitonavirIn patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] .Co-administration of Ritonavir in Patients on Tadalafil TabletsAvoid use of tadalafil tablets during the initiation of ritonavir.

Transition process

Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] . The recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period.

How Effective Is Cialis?

Effects on the eye: Sudden loss of vision could be a sign of non-arteritic ischemic optic neuropathy (NAION) and may be permanent . Hearing impairment: Cases of sudden decrease or loss of hearing have been reported with CIALIS. Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. Prolonged erection: Advise patients to seek emergency treatment if an erection lasts >4 hours. The most common adverse reaction is headache.

Other uses

To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE1.1 Pulmonary Arterial Hypertension2 DOSAGE AND ADMINISTRATION2.1 Pulmonary Arterial Hypertension2.2 Dose Adjustment in Renal Impairment2.3 Dose Adjustment in Hepatic Impairment2.4 Dose Adjustment for Use with Ritonavir3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS4.1 Concomitant Organic Nitrates4.2 Concomitant Guanylate Cyclase (GC) Stimulators4.3 Hypersensitivity Reactions5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Visual Loss5.4 Hearing Impairment5.5 Combination with Other PDE5 Inhibitors5.6 Prolonged Erection6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 Nitrates7.2 Alpha-Blockers7.3 Antihypertensives7.4 Alcohol7.5 CYP3A Inhibitors/Inducers8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.3 Females and Males of Reproductive Potential8.4 Pediatric Use8.5 Geriatric Use8.6 Renal Impairment8.7 Hepatic Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology14 CLINICAL STUDIES14.1 Tadalafil tablets for Pulmonary Arterial Hypertension14.2 Long-Term Treatment of Pulmonary Arterial Hypertension16 HOW SUPPLIED/STORAGE AND HANDLING16.1 How Supplied16.2 Storage17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed. 1 INDICATIONS AND USAGE 1.1 Pulmonary Arterial HypertensionTadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

  • The yellow Cialis pill is often preferred for its long-lasting effects.
  • It is important to disclose health conditions to your doctor before using yellow Cialis.
  • Yellow Cialis is sometimes used off-label for other conditions, under supervision.
  • The pill's color and markings help pharmacy staff identify the correct medication.
  • Cialis (yellow pills) should ideally be taken in a relaxed environment.
  • Dosage frequency of yellow Cialis varies according to individual needs.
  • The yellow Cialis pill is part of a class of drugs enhancing erectile response.
  • Side effects are often mild but should be reported to your doctor.
  • Remember that yellow Cialis should be used responsibly and as prescribed.
  • The yellow Cialis pill is effective when combined with proper lifestyle changes.
  • Men should avoid excessive doses to prevent complications.
  • Yellow Cialis has become a standard treatment for ED in many countries.

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction.

Scroll to top

Dr. med. Fabienne Gretener

Werdegang

Januar 2024 bis heute
Oberärztin SenoMed AG
Schwerpunktsweiterbildung gynäkologische Senology

März 2023 – Dezember 2023
Oberärztin, SenoMed AG Bern 20%

Januar 2023 – November 2023
Assistenzärztin Psychiatrie, Klinik Meissenberg Zug

Januar 2021 – November 2022
Assistenzärztin Gynecology und Geburtshilfe, Bürgerspital Solothurn

November 2019 – Oktober 2020
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Aarau

Januar 2017 – Juli 2019
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Olten

Paul Laszlo Bernhard

Werdegang

Jan 2024 bis heute
Facharzt SenoMed AG – Brustzentrum Bern Biel

Aug 2019 – Dez 2023
Oberarzt Frauenklinik und Brustzentrum Bürgerspital, Solothurn, Schwerpunktweiterbildung operative Gynecology und Geburtshilfe sowie Senology

Mai 2019 Facharzttitel Gynecology & Geburtshilfe

Apr 2016 – Jul 2019
Arzt in Weiterbildung, Inselspital Bern, Universitätsklinik für Frauenheilkunde

Dez 2014 – Apr 2016
Arzt in Weiterbildung, Kantonsspital Baden

Sep 2012 – Sep 2014
Arzt in Weiterbildung, Universitätsklinikum Carl Gustav Carus, Dresden

Feb 2012 – Sep 2012
Arzt in Weiterbildung, Universitätsfrauenklinik Leipzig

Nov 2011 Approbation zum Arzt

2005 – 2011
Studium der Humanmedizin an der Charité, Universitätsmedizin Berlin

Dr. med. Patrizia Sager

Werdegang

Okt 2023 bis heute
Leiterin Weiterbildungsstätte gynäkologische Senology

Feb 2018 – bis heute
Leiterin Brustzentrum Bern Biel
Practiceinhaberin SenoMed AG

Nov 2017 – bis heute
Belegärztin Salem-Spital Bern

Jan 2013 – Okt 2017
Leitung Senology Brustzentrum Frauenklinik Universitätsspital Insel, Bern

Jan 2012 – Dez 2012
Oberärztin Gynecology / Geburtshilfe, Frauenklinik Universitätsspital Insel, Bern

Nov 2010 – Dez 2011
Leitende Ärztin Gynecology und Geburtshilfe, Frauenklinik Rheinfelden (DE)

Nov 2009 – Okt 2010
Oberärztin Gynecology und Geburtshilfe, Kantonsspital Liestal

Jan 2009 – Okt 2009
Oberärztin i.V. Gynecology und Geburtshilfe, Regionalspital Interlaken

Jun 2008 – Dez 2008
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Interlaken

Aug 2007 – Mai 2008
Assistenzärztin Gynecology und Geburtshilfe, Universitätsspital Zürich

Feb 2007 – Jun 2007
Oberärztin Gynecology und Geburtshilfe, Universitätsspital Groote Schuur, Kapstadt, Südafrika

Jan 2004 – Dez 2006
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Thun

Jan 2003 – Dez 2003
Assistenzärztin Chirurgie und Orthopädie, Regionalspital Thun

Schulen, Studium & Diplome

2023
Schwerpunkt gynäkologische Senology

2014
Diplom Senology SGGG

2013
Diplom Senology: European Academy of Senology

2010
FMH Gynecology und Geburtshilfe inkl. Schwerpunkt operative Gynecology

2003
Promotion

2002
Staatsexamen in Humanmedizin

1996 – 2002
Humanmedizinstudium Universitätsspital Basel

Mitglied- und Partnerschaften

  • Schweizerische Gesellschaft für Gynecology und Geburtshilfe SGGG
  • Schweizerische Gesellschaft für Senology SGS
  • Mitglieder Arbeitsgemeinschaft Gynäkologische Onkologie AGO, Schweiz
  • European Academy of Senology EAoS
  • SAKK Project-Group breast cancer
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Verbindung der Schweizer Ärzte und Ärztinnen FMH
  • Society of women in senology SWIS
  • Vorstandsmitglied Ärztenetzwerk Bern